Genentech inks $850M upfront deal for Regor’s CDK inhibitors
WEB1 day ago · By Nick Paul Taylor Sep 30, 2024 5:30am. Roche Genentech Regor Therapeutics mergers and acquisitions. Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK ...
Genentech buys Regor's next-gen CDK inhibitors for $850M
WEB1 day ago · News Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...
Genentech To Acquire Portfolio Of Next-generation CDK …
WEB1 day ago · (RTTNews) - Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK ...
Regor to Sell Breast Cancer CDK Inhibitors to Roche Unit for …
WEB1 day ago · Sep 29, 2024 10:44pm. By Ian Walker. Regor Pharmaceuticals (USA) said it is selling a portfolio of CDK inhibitors used to treat breast cancer to Roche Holding unit Genentech for an upfront payment ...
Roche Doubles Down on Breast Cancer With $850M for Regor’s CDK ...
WEB1 day ago · A portfolio of CDK inhibitors developed by Regor Pharmaceuticals has found a home at Roche, which announced Monday it would buy the investigational cancer drugs for $850 million upfront.. Cambridge, Mass.– and China-based Regor will see two ongoing Phase I trials of CDK4 inhibitor RGT-419B through to their completion, at which time Roche’s Genentech subsidiary will take over global ...
Roche turns to a startup in search for new breast cancer drugs
WEB1 day ago · Dive Brief: Roche on Monday agreed to pay $850 million to acquire two experimental breast cancer drugs being developed by China-based biotechnology startup Regor Therapeutics. The deal hands Roche two medicines that Regor, in a statement, described as “next-generation” versions of the CDK inhibitors widely used to treat certain breast cancers.
Genentech to acquire Regor's next-gen CDK inhibitors portfolio
WEB1 day ago · Sino-American biotech Regor Pharmaceuticals has entered into a definitive purchase agreement whereby Swiss pharma major Roche (ROG: SIX) subsidiary Genentech will acquire a portfolio of next-generation CDK inhibitors from Regor for the treatment of breast cancer.
Genentech acquires Regor's CDK inhibitors for breast cancer
WEB1 day ago · Genentech has entered into an agreement with Regor Pharmaceuticals to acquire its next-generation CDK inhibitors for the treatment of breast cancer. The deal includes an upfront payment of $850 million, with additional payments contingent on the achievement of development, regulatory, and commercial milestones.
Regor Enters into a Definitive Purchase Agreement for Genentech …
WEB1 day ago · Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire/ -...
Genentech To Acquire Portfolio Of Next-generation CDK …
WEB1 day ago · Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors from Regor for the treatment of breast cancer. Regor will receive an upfront cash payment of $850 million and is eligible to …
- Some results have been removed